Get started
Author

Mathilda Cominos

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
2021 · Dean A Fennell, Sean Ewings, et al. · The Lancet Oncology · 275
PDF
Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy Predicts Recurrence and Survival in Esophageal Adenocarcinoma: A Multicenter Study in the United Kingdom
2023 · Jonathan L. Moore, Michael Green, et al. · Journal of Clinical Oncology · 39
Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma – A comparison of the FLOT and ‘MAGIC’ regimens
2022 · Jonathan L. Moore, Sacheen Kumar, et al. · European Journal of Cancer · 21
Quantification and reduction of cardiac dose in radical radiotherapy for oesophageal cancer
2005 · M Cominos, M A Mosleh-Shirazi, et al. · British Journal of Radiology · 14
Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma
2023 · Jonathan L. Moore, Manil Subesinghe, et al. · European Radiology · 12
PDF
Initial experience in staging primary oesophageal/gastro-oesophageal cancer with 18F-FDG PET/MRI
2021 · Amy R. Sharkey, Bert-Ram Sah, et al. · European Journal of Hybrid Imaging · 12
PDF
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial
2025 · Gianmarco Leone, Francesco Orlando, et al. · JAMA Oncology · 9
REsolution of Symptoms afTer Oesophago-gastric cancer REsection delphi (RESTOREd)—standardizing the definition, investigation and management of gastrointestinal symptoms and conditions after surgery
2024 · Ben E Byrne, Kwabena Siaw-Acheampong, et al. · British journal of surgery · 8
Clinical Relevance of the Tumor Location-Modified Laurén Classification System for Gastric Cancer in a Western Population
2022 · J. L. Moore, A. R. Davies, et al. · Annals of Surgical Oncology · 8
PDF
Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy
2024 · Sanjay Popat, Adam Januszewski, et al. · British Journal of Cancer · 5
PDF
CODAK: Real-World Clinical Outcomes of Patients With Unresectable, Stage III Non–Small Cell Lung Cancer Treated With Durvalumab After Chemoradiotherapy in the United Kingdom
2025 · K. Franks, D. Smith, et al. · Clinical Oncology · 3
PDF
P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial)
2017 · Sanjay Popat, Laura Hughes, et al. · Journal of Thoracic Oncology · 3
A rare case of ectopic ACTH production and carcinoid syndrome from a metastasized small bowel neuroendocrine tumour
2026 · Shalini Bhola, Janine Musselwhite, et al. · Endocrine Abstracts
264 Radiotherapy Utilisation, PCI Uptake, and Survival Outcomes in Small-Cell Lung Cancer: A Real-World Retrospective Study from the Kent Region
2026 · Farah Naaz Kazi, Jennifer Pang, et al. · Lung Cancer
103 Toxicity and treatment related adverse events of Ipilimumab and Nivolumab use in Mesothelioma - a retrospective study
2026 · Bettina Teruzzi, Pritha Roy, et al. · Lung Cancer
79 The Impact of Circulatory Tumour DNA (ctDNA) Analysis in Non-Small Cell Lung Cancer (NSCLC) Management in the NHS: A Multi-centre Retrospective Study
2026 · Rebecca Anson, Matthew Burton, et al. · Lung Cancer
78 Clinical outcomes in patients with unresectable stage III Non-Small Cell Lung Cancer (NSCLC) treated with durvalumab after chemoradiation in the United Kingdom: CODAK real-world study (NCT04667312)
2024 · Kevin Franks, Daniel Smith, et al. · Lung Cancer
142P CODAK real-world study: Interim analysis of clinical outcomes in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (CRT) in the United Kingdom
2022 · K. Franks, M. Ahmed, et al. · Immuno-Oncology Technology
Lung SABR outcomes in patients treated in a DGH using a team-based learning approach
2022 · Sola Adeleke, Alice Rendall, et al. · Lung Cancer
ASO Visual Abstract: Clinical Relevance of the Tumor Location-Modified Laurén Classification System of Gastric Cancer in a Western Population
2022 · Jonathan L. Moore, Andrew R. Davies, et al. · Annals of Surgical Oncology
PDF
SABR implementation at a regional cancer centre: first-year outcomes and challenges at the Kent Oncology Centre
2019 · S. Forner, M. Cominos, et al. · Lung Cancer
P1.13-17 Multicentre Phase II Trial of First-Line Afatinib in Patients with Suspected/Confirmed EGFR Mutant NSCLC: ctDNA and Long-Term Efficacy
2018 · S. Popat, A. Januszewski, et al. · Journal of Thoracic Oncology
PDF
64 Management of EGFR tyrosine kinase inhibitor associated skin toxicity: a single centre experience
2016 · L. Thomas, M. Hadaki, et al. · Lung Cancer
139 A retrospective review of lung cancer patients receiving whole brain radiotherapy treated at the Kent Oncology Centre (KOC) in 2014, audited against the QUARTZ trial
2016 · G. Hegarty, J.Y. Turner, et al. · Lung Cancer
66: Adjuvant chemotherapy dose delivery for completely resected NSCLC in a regional cancer centre: analysis of outcomes by age and comorbidity
2015 · S. Wood, R. Li, et al. · Lung Cancer
Works count: 39
Citation count: 409
H-index: 8
I10-index: 6
Year
Topic
Type